Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In order to evaluate the clinical significance of serum biotin and
biotinidase
in liver disease, serum biotin levels and
biotinidase
activities were determined in 83 patients with various liver diseases and 10 healthy controls. Serum biotin levels and
biotinidase
activities were determined by a simplified lactobacillus plantarum bioassay and liquid chromatography with fluorimetric detection respectively. Serum biotin levels in decompensated
liver cirrhosis
, hepatoma and fulminant hepatitis were found to be significant low compared with healthy controls, while it was significant high in autoimmune hepatitis. There was no significant difference between serum biotin levels in the other liver diseases and healthy controls. In various liver diseases except for both acute hepatitis and alcoholic liver disease
biotinidase
activities were significantly reduced than in healthy controls. Serum
biotinidase
activities were correlated with serum albumin, prothrombin time, ChE and total cholesterol respectively, suggesting that
biotinidase
activities may reflect the degree of liver damage. These results seem that biotin deficiency may occur in some cases of severe liver diseases.
...
PMID:[Clinical evaluation of serum biotin levels and biotinidase activities in patients with various liver diseases]. 238 84
To investigate whether
biotinidase
deficiency may occur in liver disease, we determined
biotinidase
activity, biotin levels, and organic acids in patients with liver disease. Serum
biotinidase
activity in patients with liver disease (2.63 +/- 1.40 nmol/min/ml) was significantly lower than in the control group (5.43 +/- 1.06 nmol/min/ml). Serum
biotinidase
activity in decompensated
liver cirrhosis
(LC) and hepatoma was significantly lower than in acute viral hepatitis (AVH), chronic viral hepatitis (CVH), and compensated LC. The mean serum level of biotin in decompensated LC (1.8 +/- 0.6 microgram/ml) and hepatoma (1.7 +/- 0.8 microgram/ml) was significantly lower than in the control group (2.5 +/- 1.0 microgram/ml), and urinary excretion of biotin was increased in patients with liver disease, particularly in decompensated LC. Biotinidase activity correlated positively with serum biotin level and correlated negatively with urinary biotin level. Moreover, in four of five patients with severe liver disease the excretion of propionate, lactate, and 3-hydroxybutyrate decreased after biotin supplementation. The data for patients with severe liver disease so resembled those for late-onset multiple carboxylase deficiency that
biotinidase
deficiency is likely in patients with severe liver disease.
...
PMID:Biotinidase activity in patients with liver disease. 826 19